CELLSEARCH® Circulating Tumor Cell Test in metastatic prostate cancer (mPC)—clinical trials and real-world case studies

Pivotal Clinical Trial—circulating tumor cells (CTCs) predict disease progression and survival in patients with mPC*1,2

Study design

Two hundred thirty-one patients with histologically confirmed mPC who were starting a new line of therapy were monitored with CTCs and prostate-specific antigen (PSA) levels at baseline and monthly thereafter.1


OS in mPC Patients with CTCs <5 vs ≥5 at Baseline (N=219)
A Reduction in CTC to Below 5 After the Initiation of Therapy Predicts Longer OS
Ability of CTC and PSA Reduction to Predict OS
Ability of CTC and PSA Reduction to Predict OS

  1. de Bono, JS, et al. Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 2008;14:6302-6309.
  2. CELLSEARCH® Circulating Tumor Cell Kit (Epithelial) Instructions for Use. Janssen Diagnostics, LLC.